The market for diagnostic labs in South Korea is expanding as a result of increasing healthcare costs, rising point-of-care diagnostics utilisation, and rising chronic diseases prevalence. However, the overall market expansion is hampered by the lack of skilled professionals.
The market for diagnostic labs was expanding steadily before the COVID-19 pandemic as cancer screening, consultations, and treatments became common. During the pandemic, the detection and diagnosis of COVID patients had a significant impact on the diagnostic lab market. The healthcare-focused IT sector offers a variety of investment opportunities, particularly in start-ups that are creating innovative drugs and diagnostic devices.
Moreover, the rising healthcare expenditure to improve the existing healthcare infrastructure in developing countries has resulted in the establishment of numerous new hospitals and diagnostic labs and the upgrade of the existing facilities. Development of new diagnostic labs in South Korea is expected to influence the growth of South Korea Diagnostic Labs Market during the forecast period.
The primary cause of death in South Korea is Cancer. 161.1 deaths per 100,000 have been observed due to cancer in 2021, which is an increase of 0.6% percent from the year 2020. Most deaths are caused due to lung cancer, followed by liver cancer.
Growing Incidences of Chronic Diseases
In South Korea, chronic diseases currently account for six of the top ten causes of mortality as a result of a dramatic increase in their prevalence over the previous few years. As a result, treating chronic illnesses has become more popular across the country. In order to manage and prevent chronic diseases, the government continues to implement several pilot programs based on the "Act on the Prevention and Management of Cardiovascular Diseases."
The prevalence of chronic disease in South Korea is around 24%.
Download Free Sample ReportIncreasing Demand for Early Detection/Screening
The goal of early disease detection is to locate individuals who are showing symptoms as soon as possible to offer them the best opportunity of making a full recovery. The effects of poor or delayed detection include a lower chance of survival, more challenging treatment, and more expensive care. Early diagnosis is a crucial public health policy because it improves disease outcomes by providing care at the earliest feasible time.
Early screening is defined as the suspected discovery of undetected disease in a community of people who appear healthy and asymptomatic utilising tests, examinations, or other methods that may be provided to the target population rapidly and inexpensively. A screening program must cover the full screening process, from inviting the target group to giving individuals who are found to have disease access to quality care. The diagnostic labs must analyse the sample for the screening programs before treating patients.
As the population is focusing on getting their tests done for early diagnosis, this factor is also driving market growth. The Covid pandemic also influenced routine health screenings and early disease identification in the population.
Market Segmentation
South Korea Diagnostic Labs market can be segmented on the basis of provider type, test type, end user, and region. Based on provider type, the market can be divided into stand alone diagnostic labs, hospital based diagnostic labs, and diagnostic chains. Based on test type, the market is divided into pathology and radiology. Based on end user, the market is further divided into
Market Players
Green Cross Laboratories, Seegene medical foundation, INFINITT Healthcare Co.,Ltd., MEDIPOST Co.,Ltd., Bio Focus Co., Ltd., Geneone Life Science. Inc., Humanpass Inc.., Ellead, Eone Diagnomics Genome Center are some of the leading players operating in the South Korea Diagnostic Labs market.
Attribute | Details |
Base Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
Report coverage | Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | By Provider Type By Test Type By End User By Region |
Regional scope | North; South; Central |
Key companies profiled | Green Cross Laboratories, Seegene medical foundation, Infinitt Healthcare Co.,Ltd., Medipost Co.,Ltd., Bio Focus Co., Ltd., Geneone Life Science Inc., Humanpass Inc., Ellead, Eone Diagnomics Genome Center |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |